Pharmacological and immunological targeting of tumor mesenchymalization

Pharmacology and Therapeutics

Volumn 170, Issue , 2017, Pages 212-225

  David, Justin M ^a   Dominguez, Charli ^a   Palena, Claudia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brachyury; Cancer vaccine; Epithelial mesenchymal transition; Stemness

Indexed keywords

CANCER VACCINE; CYANOCOBALAMIN; CYTOTOXIC AGENT; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SCREENING; CELL DIFFERENTIATION; CELL PLASTICITY; CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR MESENCHYMALIZATION; TUMOR RESISTANCE; ANIMAL; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; METASTASIS; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE;

EID: 85007610405     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.11.011     Document Type: Review

References (187)

1. Angevin, E., Tabernero, J., Elez, E., Cohen, S.J., Bahleda, R., van Laethem, J.L.,.. Kurzrock, R., A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research 20 (2014), 2192–2204.
2. Bates, R.C., DeLeo, M.J. III, Mercurio, A.M., The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Experimental Cell Research 299 (2004), 315–324.
3. Becker, C., Fantini, M.C., Schramm, C., Lehr, H.A., Wirtz, S., Nikolaev, A.,.. Neurath, M.F., TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21 (2004), 491–501.
4. Benoy, I.H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpé, S.,.. Dirix, L.Y., Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research 10 (2004), 7157–7162.
5. Bhola, N.E., Balko, J.M., Dugger, T.C., Kuba, M.G., Sanchez, V., Sanders, M.,.. Arteaga, C.L., TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. The Journal of Clinical Investigation 123 (2013), 1348–1358.
6. Blanco, M.J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios, J., Nieto, M.A., Correlation of snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21 (2002), 3241–3246.
7. Boehmerle, W., Endres, M., Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death & Disease, 2, 2011, e168.
8. Boehmerle, W., Muenzfeld, H., Springer, A., Huehnchen, P., Endres, M., Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice. Journal of Molecular Medicine 92 (2014), 889–900.
9. Bolos, V., Peinado, H., Perez-Moreno, M.A., Fraga, M.F., Esteller, M., Cano, A., The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. Journal of Cell Science 116 (2003), 499–511.
10. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E.,.. Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England Journal of Medicine 373 (2015), 1627–1639.
11. Brabletz, T., To differentiate or not–routes towards metastasis. Nature Reviews. Cancer 12 (2012), 425–436.
12. Brabletz, T., Hlubek, F., Spaderna, S., Schmalhofer, O., Hiendlmeyer, E., Jung, A., Kirchner, T., Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells, Tissues, Organs 179 (2005), 56–65.
13. Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A.,.. Kirchner, T., Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proceedings of the National Academy of Sciences of the United States of America 98 (2001), 10356–10361.
14. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P.,.. Wigginton, J.M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine 366 (2012), 2455–2465.
15. Brandolini, L., Cristiano, L., Fidoamore, A., De Pizzol, M., Di Giacomo, E., Florio, T.M.,.. Cimini, A., Targeting CXCR1 on breast cancer stem cells: Signaling pathways and clinical application modelling. Oncotarget 6 (2015), 43375–43394.
16. Byers, L.A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M.,.. Heymach, J.V., An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research 19 (2013), 279–290.
17. Cano, A., Perez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G.,.. Nieto, M.A., The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology 2 (2000), 76–83.
18. Carmody, L.C., Germain, A.R., VerPlank, L., Nag, P.P., Munoz, B., Perez, J.R., Palmer, M.A., Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. Journal of Biomolecular Screening 17 (2012), 1204–1210.
19. Casilli, F., Bianchini, A., Gloaguen, I., Biordi, L., Alesse, E., Festuccia, C.,.. Bertini, R., Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochemical Pharmacology 69 (2005), 385–394.
20. Chaffer, C.L., Brennan, J.P., Slavin, J.L., Blick, T., Thompson, E.W., Williams, E.D., Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Research 66 (2006), 11271–11278.
21. Chen, L., Gibbons, D.L., Goswami, S., Cortez, M.A., Ahn, Y.H., Byers, L.A.,.. Qin, F.X., Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 5, 2014, 5241.
22. Chua, K.N., Sim, W.J., Racine, V., Lee, S.Y., Goh, B.C., Thiery, J.P., A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS One, 7, 2012, e33183.
23. Creighton, C.J., Li, X., Landis, M., Dixon, J.M., Neumeister, V.M., Sjolund, A.,.. Chang, J.C., Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America 106 (2009), 13820–13825.
24. David, J.M., Dominguez, C., Hamilton, D.H., Palena, C., The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines (Basel), 4, 2016 (pii: E22).
25. David, J.M., Owens, T.A., Inge, L.J., Bremner, R.M., Rajasekaran, A.K., Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma. Molecular Cancer Therapeutics 13 (2014), 788–799.
26. Derynck, R., Akhurst, R.J., Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nature Cell Biology 9 (2007), 1000–1004.
27. Dijkgraaf, E.M., Santegoets, S.J., Reyners, A.K., Goedemans, R., Wouters, M.C., Kenter, G.G.,.. Kroep, J.R., A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Annals of Oncology 26 (2015), 2141–2149.
28. Du, R., Wu, S., Lv, X., Fang, H., Wu, S., Kang, J., Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research, 33, 2014, 105.
29. Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M.,.. Foisner, R., DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24 (2005), 2375–2385.
30. Elloul, S., Elstrand, M.B., Nesland, J.M., Trope, C.G., Kvalheim, G., Goldberg, I.,.. Davidson, B., Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103 (2005), 1631–1643.
31. Engelman, J.A., Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nature Reviews. Cancer 9 (2009), 550–562.
32. Espineda, C.E., Chang, J.H., Twiss, J., Rajasekaran, S.A., Rajasekaran, A.K., Repression of Na,K-ATPase beta1-subunit by the transcription factor snail in carcinoma. Molecular Biology of the Cell 15 (2004), 1364–1373.
33. Feniger-Barish, R., Yron, I., Meshel, T., Matityahu, E., Ben-Baruch, A., IL-8-induced migratory responses through CXCR1 and CXCR2: association with phosphorylation and cellular redistribution of focal adhesion kinase. Biochemistry 42 (2003), 2874–2886.
34. Fernando, R.I., Castillo, M.D., Litzinger, M., Hamilton, D.H., Palena, C., IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Research 71 (2011), 5296–5306.
35. Fernando, R.I., Hamilton, D.H., Dominguez, C., David, J.M., McCampbell, K.K., Palena, C., IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget 71 (2016), 5296–5306.
36. Fernando, R.I., Litzinger, M., Trono, P., Hamilton, D.H., Schlom, J., Palena, C., The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. The Journal of Clinical Investigation 120 (2010), 533–544.
37. Fischer, K.R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S.T.,.. Gao, D., Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
38. Fu, X.T., Dai, Z., Song, K., Zhang, Z.J., Zhou, Z.J., Zhou, S.L.,.. Fan, J., Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. International Journal of Oncology 46 (2015), 587–596.
39. Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z.,.. Munshi, N.C., A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research 15 (2009), 7144–7152.
40. Gabitzsch, E.S., Tsang, K.Y., Palena, C., David, J.M., Fantini, M., Kwilas, A.,.. Schlom, J., The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget 6 (2015), 31344–31359.
41. Garber, K., Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. Journal of the National Cancer Institute, 100(232-233), 2008, 239.
42. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P.,.. Gandhi, L., Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine 372 (2015), 2018–2028.
43. Germain, A.R., Carmody, L.C., Nag, P.P., Morgan, B., Verplank, L., Fernandez, C.,.. Munoz, B., Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorganic & Medicinal Chemistry Letters 23 (2013), 1834–1838.
44. Ginestier, C., Liu, S., Diebel, M.E., Korkaya, H., Luo, M., Brown, M.,.. Wicha, M.S., CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. The Journal of Clinical Investigation 120 (2010), 485–497.
45. Gravdal, K., Halvorsen, O.J., Haukaas, S.A., Akslen, L.A., A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Research 13 (2007), 7003–7011.
46. Gulley, J.L., Madan, R.A., Tsang, K.Y., Jochems, C., Marte, J.L., Farsaci, B.,.. Schlom, J., Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunology Research 2 (2014), 133–141.
47. Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., Lander, E.S., Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138 (2009), 645–659.
48. Gurney, A., Axelrod, F., Bond, C.J., Cain, J., Chartier, C., Donigan, L.,.. Hoey, T., Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 11717–11722.
49. Haase, V.H., Oxygen regulates epithelial-to-mesenchymal transition: Insights into molecular mechanisms and relevance to disease. Kidney International 76 (2009), 492–499.
50. Hamilton, D.H., Matthews Griner, L., Keller, J.M., Hu, X., Southall, N., Marugan, J.,.. Palena, C., Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer. Clinical Cancer Research, 2016.
51. Hamilton, D.H., Roselli, M., Ferroni, P., Costarelli, L., Cavaliere, F., Taffuri, M.,.. Guadagni, F., Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. Endocrine-Related Cancer 23 (2016), 783–796.
52. Hamilton, D.H., Litzinger, M.T., Jales, A., Huang, B., Fernando, R.I., Hodge, J.W.,.. Palena, C., Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 4 (2013), 1777–1790.
53. Haro, A., Yano, T., Kohno, M., Yoshida, T., Koga, T., Okamoto, T.,.. Maehara, Y., Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. Annals of Surgical Oncology 20:Suppl. 3 (2013), S509–S516.
54. Hay, E.D., An overview of epithelio-mesenchymal transformation. Acta Anatomica (Basel) 154 (1995), 8–20.
55. Hay, E.D., The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Developmental Dynamics 233 (2005), 706–720.
56. Heery, C.R., Donahue, R.N., Lepone, L., Grenga, I., Richards, J., Metenou, S.,.. Schlom, J., Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses. Journal for ImmunoTherapy of Cancer 3 (2015), 1–2.
57. Heery, C.R., Singh, B.H., Rauckhorst, M., Marte, J.L., Donahue, R.N., Grenga, I.,.. Gulley, J.L., Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury. Cancer Immunology Research 3 (2015), 1248–1256.
58. Herbertz, S., Sawyer, J.S., Stauber, A.J., Gueorguieva, I., Driscoll, K.E., Estrem, S.T.,.. Lahn, M.M., Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design, Development and Therapy 9 (2015), 4479–4499.
59. Herbst, A., Jurinovic, V., Krebs, S., Thieme, S.E., Blum, H., Goke, B., Kolligs, F.T., Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics, 15, 2014, 74.
60. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S.,.. Hodi, F.S., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
61. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S., Nakajima, K., Koyama, K., Iwamatsu, A., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324 (1986), 73–76.
62. Hiscox, S., Jiang, W.G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R.,.. Nicholson, R.I., Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. International Journal of Cancer 118 (2006), 290–301.
63. Holmes, W.E., Lee, J., Kuang, W.J., Rice, G.C., Wood, W.I., Structure and functional expression of a human interleukin-8 receptor. Science 253 (1991), 1278–1280.
64. Huang, B., Cohen, J.R., Fernando, R.I., Hamilton, D.H., Litzinger, M.T., Hodge, J.W., Palena, C., The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death & Disease, 4, 2013, e682.
65. Huang, R.Y., Wong, M.K., Tan, T.Z., Kuay, K.T., Ng, A.H., Chung, V.Y., Chu, Y.S., Matsumura, N., Lai, H.C., Lee, Y.F., Sim, W.J., Chai, C., Pietschmann, E., Mori, S., Low, J.J., Choolani, M., Thiery, J.P., An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death & Disease, 4, 2013, e915.
66. Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.D.,.. Bar-Eli, M., Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. The American Journal of Pathology 161 (2002), 125–134.
67. Hudes, G., Tagawa, S.T., Whang, Y.E., Qi, M., Qin, X., Puchalski, T.A.,.. Eisenberger, M., A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investigational New Drugs 31 (2013), 669–676.
68. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S.,.. Lo, R.S., Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
69. Huynh, T.P., Barwe, S.P., Lee, S.J., McSpadden, R., Franco, O.E., Hayward, S.W.,.. Rajasekaran, A.K., Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expression. PLoS One, 10, 2015, e0122442.
70. Imajyo, I., Sugiura, T., Kobayashi, Y., Shimoda, M., Ishii, K., Akimoto, N.,.. Mori, Y., T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. International Journal of Oncology 41 (2012), 1985–1995.
71. Jaschinski, F., Rothhammer, T., Jachimczak, P., Seitz, C., Schneider, A., Schlingensiepen, K.H., The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Current Pharmaceutical Biotechnology 12 (2011), 2203–2213.
72. Kadowaki, T., Wilder, E., Klingensmith, J., Zachary, K., Perrimon, N., The segment polarity gene porcupine encodes a putative multitransmembrane protein involved in Wingless processing. Genes & Development 10 (1996), 3116–3128.
73. Kajiyama, H., Shibata, K., Terauchi, M., Yamashita, M., Ino, K., Nawa, A., Kikkawa, F., Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. International Journal of Oncology 31 (2007), 277–283.
74. Kalluri, R., Weinberg, R.A., The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 119 (2009), 1420–1428.
75. Kang, S., Tanaka, T., Kishimoto, T., Therapeutic uses of anti-interleukin-6 receptor antibody. International Immunology 27 (2015), 21–29.
76. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 (1988), 83–85.
77. Ketola, K., Vuoristo, A., Orešič, M., Kallioniemi, O., Iljin, K., Monensin induced oxidative stress reduces prostate cancer cell migration and cancer stem cell population. Lushchak, V., Gospodaryov, D.V., (eds.) Oxidative stress and diseases, 2012, InTech.
78. Kilic, N., Feldhaus, S., Kilic, E., Tennstedt, P., Wicklein, D., Wasielewski, R.,.. Schumacher, U., Brachyury expression predicts poor prognosis at early stages of colorectal cancer. European Journal of Cancer 47 (2011), 1080–1085.
79. Kim, H.P., Han, S.W., Song, S.H., Jeong, E.G., Lee, M.Y., Hwang, D.,.. Kim, T.Y., Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene 33 (2014), 3334–3341.
80. Kim, H.Y., Jackson, T.R., Davidson, L.A., On the role of mechanics in driving mesenchymal-to-epithelial transitions. Seminars in Cell & Developmental Biology, 2016.
81. Knall, C., Young, S., Nick, J.A., Buhl, A.M., Worthen, G.S., Johnson, G.L., Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. The Journal of Biological Chemistry 271 (1996), 2832–2838.
82. Kolev, V.N., Wright, Q.G., Vidal, C.M., Ring, J.E., Shapiro, I.M., Ricono, J.,.. Xu, Q., PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Research 75 (2015), 446–455.
83. Kothari, A.N., Mi, Z., Zapf, M., Kuo, P.C., Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clinical and Translational Medicine, 3, 2014, 35.
84. Kurrey, N.K., Jalgaonkar, S.P., Joglekar, A.V., Ghanate, A.D., Chaskar, P.D., Doiphode, R.Y., Bapat, S.A., Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27 (2009), 2059–2068.
85. Larocca, C., Cohen, J.R., Fernando, R.I., Huang, B., Hamilton, D.H., Palena, C., An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Molecular Cancer Therapeutics 12 (2013), 1805–1815.
86. Le, P.N., McDermott, J.D., Jimeno, A., Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacology & Therapeutics 146 (2015), 1–11.
87. Lebrun, J.J., The dual role of TGFbeta in human cancer: from tumor suppression to cancer metastasis. ISRN Molecular Biology, 2012, 2012, 381428.
88. Lenz, H.J., Kahn, M., Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Science 105 (2014), 1087–1092.
89. Lim, J., Thiery, J.P., Epithelial-mesenchymal transitions: insights from development. Development 139 (2012), 3471–3486.
90. Liu, Y.N., Chang, T.H., Tsai, M.F., Wu, S.G., Tsai, T.H., Chen, H.Y.,.. Shih, J.Y., IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget 6 (2015), 10415–10431.
91. Liu, J., Pan, S., Hsieh, M.H., Ng, N., Sun, F., Wang, T.,.. Harris, J.L., Targeting Wnt-driven cancer through the inhibition of porcupine by LGK974. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 20224–20229.
92. Lombaerts, M., van Wezel, T., Philippo, K., Dierssen, J.W., Zimmerman, R.M., Oosting, J.,.. Cleton-Jansen, A.M., E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. British Journal of Cancer 94 (2006), 661–671.
93. Lonning, S., Mannick, J., McPherson, J.M., Antibody targeting of TGF-beta in cancer patients. Current Pharmaceutical Biotechnology 12 (2011), 2176–2189.
94. Lou, Y., Diao, L., Cuentas, E.R., Denning, W.L., Chen, L., Fan, Y.H.,.. Gibbons, D.L., Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research 22 (2016), 3630–3642.
95. Lu, D., Choi, M.Y., Yu, J., Castro, J.E., Kipps, T.J., Carson, D.A., Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proceedings of the National Academy of Sciences of the United States of America 108 (2011), 13253–13257.
96. MacManus, C.F., Pettigrew, J., Seaton, A., Wilson, C., Maxwell, P.J., Berlingeri, S.,.. Waugh, D.J., Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Molecular Cancer Research 5 (2007), 737–748.
97. Madan, R.A., Bilusic, M., Heery, C., Schlom, J., Gulley, J.L., Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Seminars in Oncology 39 (2012), 296–304.
98. Mak, M.P., Tong, P., Diao, L., Cardnell, R.J., Gibbons, D.L., William, W.N.,.. Byers, L.A., A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clinical Cancer Research 22 (2016), 609–620.
99. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y.,.. Weinberg, R.A., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
100. Marotta, L.L., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S.R.,.. Polyak, K., The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. The Journal of Clinical Investigation 121 (2011), 2723–2735.
101. Massague, J., TGFbeta in cancer. Cell 134 (2008), 215–230.
102. McDonald, O.G., Wu, H., Timp, W., Doi, A., Feinberg, A.P., Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nature Structural & Molecular Biology 18 (2011), 867–874.
103. Mejlvang, J., Kriajevska, M., Vandewalle, C., Chernova, T., Sayan, A.E., Berx, G.,.. Tulchinsky, E., Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Molecular Biology of the Cell 18 (2007), 4615–4624.
104. Mian, B.M., Dinney, C.P., Bermejo, C.E., Sweeney, P., Tellez, C., Yang, X.D.,.. Bar-Eli, M., Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clinical Cancer Research 9 (2003), 3167–3175.
105. Miao, J.W., Liu, L.J., Huang, J., Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma. International Journal of Oncology 45 (2014), 165–176.
106. Micalizzi, D.S., Farabaugh, S.M., Ford, H.L., Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. Journal of Mammary Gland Biology and Neoplasia 15 (2010), 117–134.
107. Mitani, M., Yamanishi, T., Miyazaki, Y., Otake, N., Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrobial Agents and Chemotherapy 9 (1976), 655–660.
108. Morris, J.C., Tan, A.R., Olencki, T.E., Shapiro, G.I., Dezube, B.J., Reiss, M.,.. Lawrence, D.P., Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One, 9, 2014, e90353.
109. Muellner, M.K., Mair, B., Ibrahim, Y., Kerzendorfer, C., Lechtermann, H., Trefzer, C.,.. Nijman, S.M., Targeting a cell state common to triple-negative breast cancers. Molecular Systems Biology, 11, 2015, 789.
110. Naujokat, C., Steinhart, R., Salinomycin as a drug for targeting human cancer stem cells. Journal of Biomedicine & Biotechnology, 2012, 2012, 950658.
111. Nieto, M.A., Cano, A., The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Seminars in Cancer Biology 22 (2012), 361–368.
112. Nusse, R., van Ooyen, A., Cox, D., Fung, Y.K., Varmus, H., Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307 (1984), 131–136.
113. Okamoto, M., Lee, C., Oyasu, R., Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Research 57 (1997), 141–146.
114. Padua, D., Massague, J., Roles of TGFbeta in metastasis. Cell Research 19 (2009), 89–102.
115. Palena, C., Hamilton, D.H., Immune targeting of tumor epithelial-mesenchymal transition via brachyury-based vaccines. Advances in Cancer Research 128 (2015), 69–93.
116. Palena, C., Hamilton, D.H., Fernando, R.I., Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncology 8 (2012), 713–722.
117. Palena, C., Polev, D.E., Tsang, K.Y., Fernando, R.I., Litzinger, M., Krukovskaya, L.L.,.. Schlom, J., The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clinical Cancer Research 13 (2007), 2471–2478.
118. Palena, C., Roselli, M., Litzinger, M.T., Ferroni, P., Costarelli, L., Spila, A.,.. Guadagni, F., Overexpression of the EMT driver brachyury in breast carcinomas: Association with poor prognosis. Journal of the National Cancer Institute, 106, 2014.
119. Pattabiraman, D.R., Weinberg, R.A., Tackling the cancer stem cells - What challenges do they pose?. Nature Reviews. Drug Discovery 13 (2014), 497–512.
120. Pedersen, S.F., Hoffmann, E.K., Novak, I., Cell volume regulation in epithelial physiology and cancer. Frontiers in Physiology, 4, 2013, 233.
121. Peinado, H., Ballestar, E., Esteller, M., Cano, A., Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Molecular and Cellular Biology 24 (2004), 306–319.
122. Pine, S.R., Mechanic, L.E., Enewold, L., Chaturvedi, A.K., Katki, H.A., Zheng, Y.L.,.. Harris, C.C., Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. Journal of the National Cancer Institute 103 (2011), 1112–1122.
123. Pinto, F., Campanella, N.C., Abrahao-Machado, L.F., Scapulatempo-Neto, C., de Oliveira, A.T., Brito, M.J.,.. Reis, R.M., The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival. Gastric Cancer 19 (2016), 651–659.
124. Pinto, F., Pertega-Gomes, N., Pereira, M.S., Vizcaino, J.R., Monteiro, P., Henrique, R.M.,.. Reis, R.M., T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clinical Cancer Research 20 (2014), 4949–4961.
125. Porta, C., Paglino, C., Mosca, A., Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology, 4, 2014, 64.
126. Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C.,.. Vogelzang, N.J., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
127. Prat, A., Parker, J.S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J.I.,.. Perou, C.M., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research, 12, 2010, R68.
128. Qu, Z., Sun, F., Zhou, J., Li, L., Shapiro, S.D., Xiao, G., Interleukin-6 prevents the initiation but enhances the progression of lung cancer. Cancer Research 75 (2015), 3209–3215.
129. Rajasekaran, S.A., Huynh, T.P., Wolle, D.G., Espineda, C.E., Inge, L.J., Skay, A.,.. Rajasekaran, A.K., Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Molecular Cancer Therapeutics 9 (2010), 1515–1524.
130. Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F.,.. Stanger, B.Z., EMT and dissemination precede pancreatic tumor formation. Cell 148 (2012), 349–361.
131. Ribas, A., Hamid, O., Daud, A., Hodi, F.S., Wolchok, J.D., Kefford, R.,.. Robert, C., Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315 (2016), 1600–1609.
132. Riccioni, R., Dupuis, M.L., Bernabei, M., Petrucci, E., Pasquini, L., Mariani, G.,.. Testa, U., The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells, Molecules & Diseases 45 (2010), 86–92.
133. Richard, G., Dalle, S., Monet, M.A., Ligier, M., Boespflug, A., Pommier, R.M.,.. Caramel, J., ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Molecular Medicine, 2016 (pii: e201505971).
134. Rodon, J., Carducci, M.A., Sepulveda-Sanchez, J.M., Azaro, A., Calvo, E., Seoane, J.,.. Baselga, J., First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clinical Cancer Research 21 (2015), 553–560.
135. Rokavec, M., Oner, M.G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D.,.. Hermeking, H., IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. The Journal of Clinical Investigation 124 (2014), 1853–1867.
136. Rollins, B.J., Chemokines. Blood 90 (1997), 909–928.
137. Roselli, M., Fernando, R.I., Guadagni, F., Spila, A., Alessandroni, J., Palmirotta, R.,.. Palena, C., Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: An opportunity for novel interventions against lung cancer. Clinical Cancer Research 18 (2012), 3868–3879.
138. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A.,.. Dreicer, R., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
139. Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E.,.. Dirix, L.Y., Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer 103 (2003), 642–646.
140. Sampson, V.B., David, J.M., Puig, I., Patil, P.U., de Herreros, A.G., Thomas, G.V., Rajasekaran, A.K., Wilms’ tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma. PLoS One, 9, 2014, e102041.
141. Sarkar, D., Shields, B., Davies, M.L., Muller, J., Wakeman, J.A., BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. International Journal of Cancer 130 (2012), 328–337.
142. Savagner, P., Epithelial-mesenchymal transitions: From cell plasticity to concept elasticity. Current Topics in Developmental Biology 112 (2015), 273–300.
143. Saxena, M., Stephens, M.A., Pathak, H., Rangarajan, A., Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death & Disease, 2, 2011, e179.
144. Schliekelman, M.J., Taguchi, A., Zhu, J., Dai, X., Rodriguez, J., Celiktas, M.,.. Hanash, S.M., Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Research 75 (2015), 1789–1800.
145. Schlingensiepen, K.H., Jaschinski, F., Lang, S.A., Moser, C., Geissler, E.K., Schlitt, H.J.,.. Schneider, A., Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Science 102 (2011), 1193–1200.
146. Schlom, J., Hodge, J.W., Palena, C., Tsang, K.Y., Jochems, C., Greiner, J.W.,.. Gulley, J.L., Therapeutic cancer vaccines. Advances in Cancer Research 121 (2014), 67–124.
147. Serova, M., Tijeras-Raballand, A., Dos Santos, C., Albuquerque, M., Paradis, V., Neuzillet, C.,.. de Gramont, A., Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 6 (2015), 21614–21627.
148. Shah, A.N., Summy, J.M., Zhang, J., Park, S.I., Parikh, N.U., Gallick, G.E., Development and characterization of gemcitabine-resistant pancreatic tumor cells. Annals of Surgical Oncology 14 (2007), 3629–3637.
149. Shaik, M.S., Chatterjee, A., Singh, M., Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. The Journal of Pharmacy and Pharmacology 56 (2004), 899–907.
150. Shintani, Y., Fujiwara, A., Kimura, T., Kawamura, T., Funaki, S., Minami, M., Okumura, M., IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. Journal of Thoracic Oncology 11 (2016), 1482–1492.
151. Shiota, M., Bishop, J.L., Nip, K.M., Zardan, A., Takeuchi, A., Cordonnier, T.,.. Zoubeidi, A., Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Research 73 (2013), 3109–3119.
152. Shirakihara, T., Saitoh, M., Miyazono, K., Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Molecular Biology of the Cell 18 (2007), 3533–3544.
153. Skov, L., Beurskens, F.J., Zachariae, C.O., Reitamo, S., Teeling, J., Satijn, D.,.. van de Winkel, J.G., IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. Journal of Immunology 181 (2008), 669–679.
154. Son, J.Y., Park, S.Y., Kim, S.J., Lee, S.J., Park, S.A., Kim, M.J.,.. Sheen, Y.Y., EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Molecular Cancer Therapeutics 13 (2014), 1704–1716.
155. Soundararajan, R., Paranjape, A.N., Barsan, V., Chang, J.T., Mani, S.A., A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome. Scientific Reports, 5, 2015, 11766.
156. Staff, S., Isola, J., Jumppanen, M., Tanner, M., Aurora-A gene is frequently amplified in basal-like breast cancer. Oncology Reports 23 (2010), 307–312.
157. Sullivan, N.J., Sasser, A.K., Axel, A.E., Vesuna, F., Raman, V., Ramirez, N.,.. Hall, B.M., Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28 (2009), 2940–2947.
158. Tai, D., Wells, K., Arcaroli, J., Vanderbilt, C., Aisner, D.L., Messersmith, W.A., Lieu, C.H., Targeting the WNT signaling pathway in cancer therapeutics. The Oncologist 20 (2015), 1189–1198.
159. Tan, T.Z., Miow, Q.H., Miki, Y., Noda, T., Mori, S., Huang, R.Y., Thiery, J.P., Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Molecular Medicine 6 (2014), 1279–1293.
160. Tang, H.M., Kuay, K.T., Koh, P.F., Asad, M., Tan, T.Z., Chung, V.Y.,.. Huang, R.J., An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers. Cell Death Discovery, 2, 2016, 16041.
161. Tarin, D., Thompson, E.W., Newgreen, D.F., The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Research 65 (2005), 5996–6000 (discussion 6000-5991).
162. Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
163. Thomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ramnarine, N.,.. Haley, J.D., Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Research 65 (2005), 9455–9462.
164. Thomson, S., Petti, F., Sujka-Kwok, I., Epstein, D., Haley, J.D., Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clinical & Experimental Metastasis 25 (2008), 843–854.
165. Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.H., Moustakas, A., Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. The Journal of Cell Biology 174 (2006), 175–183.
166. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F.,.. Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 366 (2012), 2443–2454.
167. Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S., Yang, J., Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22 (2012), 725–736.
168. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L.,.. Ribas, A., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
169. Tumova, L., Pombinho, A.R., Vojtechova, M., Stancikova, J., Gradl, D., Krausova, M.,.. Korinek, V., Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Molecular Cancer Therapeutics 13 (2014), 812–822.
170. Turner, M., Schweighoffer, E., Colucci, F., Di Santo, J.P., Tybulewicz, V.L., Tyrosine kinase SYK: Essential functions for immunoreceptor signalling. Immunology Today 21 (2000), 148–154.
171. Vega, S., Morales, A.V., Ocana, O.H., Valdes, F., Fabregat, I., Nieto, M.A., Snail blocks the cell cycle and confers resistance to cell death. Genes & Development 18 (2004), 1131–1143.
172. Wang, Y., Shang, Y., Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Experimental Cell Research 319 (2013), 160–169.
173. Willert, K., Brown, J.D., Danenberg, E., Duncan, A.W., Weissman, I.L., Reya, T.,.. Nusse, R., Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423 (2003), 448–452.
174. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M.,.. Sznol, M., Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine 369 (2013), 122–133.
175. Wu, S., Liu, S., Liu, Z., Huang, J., Pu, X., Li, J.,.. Xu, J., Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One, 10, 2015, e0123976.
176. Xia, P., Xu, X.Y., PI3K/Akt/mTOR signaling pathway in cancer stem cells: From basic research to clinical application. American Journal of Cancer Research 5 (2015), 1602–1609.
177. Yadav, A., Kumar, B., Datta, J., Teknos, T.N., Kumar, P., IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Molecular Cancer Research 9 (2011), 1658–1667.
178. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C.,.. Weinberg, R.A., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 (2004), 927–939.
179. Yook, J.I., Li, X.Y., Ota, I., Hu, C., Kim, H.S., Kim, N.H.,.. Weiss, S.J., A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nature Cell Biology 8 (2006), 1398–1406.
180. Yoon, M.J., Kang, Y.J., Kim, I.Y., Kim, E.H., Lee, J.A., Lim, J.H.,.. Choi, K.S., Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 34 (2013), 1918–1928.
181. Yu, M., Bardia, A., Wittner, B.S., Stott, S.L., Smas, M.E., Ting, D.T.,.. Maheswaran, S., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 (2013), 580–584.
182. Zhan, T., Rindtorff, N., Boutros, M., Wnt signaling in cancer. Oncogene, 2016, 10.1038/onc.2016.1304.
183. Zhang, Y.E., Non-Smad pathways in TGF-beta signaling. Cell Research 19 (2009), 128–139.
184. Zhang, C., Lu, Y., Li, Q., Mao, J., Hou, Z., Yu, X.,.. Li, L., Salinomycin suppresses TGF-beta1-induced epithelial-to-mesenchymal transition in MCF-7 human breast cancer cells. Chemico-Biological Interactions 248 (2016), 74–81.
185. Zhang, P., Sun, Y., Ma, L., ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14 (2015), 481–487.
186. Zhao, P., Xia, G., Dong, S., Jiang, Z.X., Chen, M., An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors. Biomaterials 93 (2016), 1–9.
187. Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H.,.. Kalluri, R., Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.